Horizon Therapeutics Plc (HZNP) – Strategy, SWOT and Corporate Finance Report

Horizon Therapeutics Plc (HZNP) – Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360˚ view of the company

Key Highlights

Horizon Therapeutics Plc (Horizon Therapeutics) formerly Horizon Pharma plc, is a pharmaceutical company, which develops and commercializes medical products for the treatment of rare, autoimmune, arthritis and severe inflammatory diseases. It markets medicines through its orphan, primary care and rheumatology business units. A few of the company’s marketed products include Actimmune, Buphenyl, Duexis, Krystexxa, Pennsaid, Procysbi, Quinsair, Ravicti, Rayos, Uplinza, Tepezza and Vimovo. Horizon Therapeutics provides products and services to patients and healthcare professionals in the US. The company operates through offices in the US, Switzerland, Luxembourg, Bermuda, Germany, Canada, and Israel. Horizon Therapeutics is headquartered in Dublin, Ireland.

Scope

• Detailed information on Horizon Therapeutics Plc required for business and competitor intelligence needs

• A study of the major internal and external factors affecting Horizon Therapeutics Plc in the form of a SWOT analysis

• An in-depth view of the business model of Horizon Therapeutics Plc including a breakdown and examination of key business segments

• News about Horizon Therapeutics Plc, such as business expansion, restructuring, and contract wins

• Large number of easy-to-grasp charts and graphs that present important data and key trends

Reasons to buy

• Gain understanding of Horizon Therapeutics Plc and the factors that influence its strategies.

• Track strategic initiatives of the company and latest corporate news and actions.

• Assess Horizon Therapeutics Plc as a prospective partner, vendor or supplier.

• Support sales activities by understanding your customers' businesses better.

• Stay up to date on Horizon Therapeutics Plcs business structure, strategy and prospects.

Note: Some sections may be missing if data is unavailable for the company.

Companies mentioned

Acorda Therapeutics Inc

Sucampo Pharmaceuticals Inc

Option Care Health Inc

Arena Pharmaceuticals Inc

Aeglea BioTherapeutics Inc

Acorda Therapeutics Inc

Option Care Health Inc

Sucampo Pharmaceuticals Inc

Arena Pharmaceuticals Inc

Aeglea BioTherapeutics Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Section 1 - About the Company

Horizon Therapeutics Plc - Key Facts

Horizon Therapeutics Plc - Key Employees

Horizon Therapeutics Plc - Key Employee Biographies

Horizon Therapeutics Plc - Major Products and Services

Horizon Therapeutics Plc - History

Horizon Therapeutics Plc - Company Statement

Horizon Therapeutics Plc - Locations And Subsidiaries

Head Office

Other Locations & Subsidiaries

Section 2 – Company Analysis

Company Overview

Horizon Therapeutics Plc - Business Description

Product Category: Actimmune

Performance

Product Category: Buphenyl

Performance

Product Category: Duexis

Performance

Product Category: Krystexxa

Performance

Product Category: Pennsaid 2%

Performance

Product Category: Procysbi

Performance

Product Category: Quinsair

Performance

Product Category: Ravicti

Performance

Product Category: Rayos

Performance

Product Category: Tepezza

Performance

Product Category: Uplizna

Performance

Product Category: Vimovo

Performance

Geographical Segment: Rest of World

Performance

Geographical Segment: United States

Performance

R&D Overview

Horizon Therapeutics Plc - Corporate Strategy

Horizon Therapeutics Plc - SWOT Analysis

SWOT Analysis - Overview

Horizon Therapeutics Plc - Strengths

Horizon Therapeutics Plc - Weaknesses

Horizon Therapeutics Plc - Opportunities

Horizon Therapeutics Plc - Threats

Horizon Therapeutics Plc - Key Competitors

Section 3 – Company Financial Ratios

Financial Ratios - Capital Market Ratios

Financial Ratios - Annual Ratios

Performance Chart

Financial Performance

Financial Ratios - Interim Ratios

Financial Ratios - Ratio Charts

Section 4 – Company’s Lifesciences Financial Deals and Alliances

Horizon Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Year, 2017 to YTD 2023

Horizon Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Type, 2017 to YTD 2023

Horizon Therapeutics Plc, Recent Deals Summary

Section 5 – Company’s Recent Developments

Mar 01, 2023: Horizon Therapeutics plc Reports Fourth-Quarter and Full-Year 2022 Financial Results

Feb 28, 2023: Horizon Therapeutics opens applications for RAREis Global Advocate Grant Program

Dec 13, 2022: Amgen agrees to acquire Horizon Therapeutics for $27.8bn

Dec 11, 2022: Statement from Sanofi regarding Horizon Therapeutics

Nov 24, 2022: Xeris and Horizon enter partnership to develop teprotumumab

Nov 17, 2022: Horizon and Johns Hopkins partner for autoimmunity and inflammation research

Nov 16, 2022: Horizon Therapeutics announces scientific collaboration with leading research institution to advance research in autoimmunity and inflammation

Nov 02, 2022: Horizon Therapeutics Reports Third-Quarter 2022 Financial Results; Increases Full-Year 2022 Net Sales and Adjusted EBITDA Guidance

Nov 02, 2022: New data reveal molecular drivers of thyroid eye disease (TED) may remain activated in patients with low clinical activity score (CAS)

Sep 21, 2022: Horizon Therapeutics announces EB research partnership receives 2022 Horizon Prize, powered by MIT Solve

Section 6 – Appendix

Methodology

Ratio Definitions

About MarketLine

Contact Us

Disclaimer

List of Tables

List of Tables

Horizon Therapeutics Plc, Key Facts

Horizon Therapeutics Plc, Key Employees

Horizon Therapeutics Plc, Key Employee Biographies

Horizon Therapeutics Plc, Major Products and Services

Horizon Therapeutics Plc, History

Horizon Therapeutics Plc, Subsidiaries

Horizon Therapeutics Plc, Key Competitors

Horizon Therapeutics Plc, Ratios based on current share price

Horizon Therapeutics Plc, Annual Ratios

Horizon Therapeutics Plc, Annual Ratios (Cont…1)

Horizon Therapeutics Plc, Annual Ratios (Cont…2)

Horizon Therapeutics Plc, Interim Ratios

Horizon Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Year, 2017 to YTD 2023

Horizon Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Type, 2017 to YTD 2023

Horizon Therapeutics Plc, Recent Deals Summary

Currency Codes

Capital Market Ratios

Equity Ratios

Profitability Ratios

Cost Ratios

Liquidity Ratios

Leverage Ratios

Efficiency Ratios

List of Figures

List of Figures

Horizon Therapeutics Plc, Performance Chart (2018 – 2022)

Horizon Therapeutics Plc, Ratio Charts

Horizon Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Year, 2017 to YTD 2023

Horizon Therapeutics Plc, Pharmaceuticals & Healthcare, Deals by Type, 2017 to YTD 2023

    Pricing

Discounts available for multiple purchases.

reportstore@marketline.com
+44 20 7947 2960

Saved reports